Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group. Sorensen PS, et al. Lancet. 2003 Oct 11;362(9391):1184-91. doi: 10.1016/S0140-6736(03)14541-2. Lancet. 2003. PMID: 14568740 Clinical Trial.
Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients.
Harbo HF, Datta P, Oturai A, Ryder LP, Sawcer S, Setakis E, Akesson E, Celius EG, Modin H, Sandberg-Wollheim M, Myhr KM, Andersen O, Hillert J, Sorensen PS, Svejgaard A, Compston A, Vartdal F, Spurkland A. Harbo HF, et al. Among authors: sorensen ps. J Neuroimmunol. 2003 Oct;143(1-2):101-6. doi: 10.1016/j.jneuroim.2003.08.021. J Neuroimmunol. 2003. PMID: 14575924
Antibodies to IFN-beta: the Danish National IFN-beta Project.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group; Danish Interferon-beta Project. Sorensen PS, et al. Neurology. 2003 Nov 11;61(9 Suppl 5):S27-8. doi: 10.1212/01.wnl.0000092362.44313.b6. Neurology. 2003. PMID: 14610108 Clinical Trial. No abstract available.
Multiple sclerosis: pathophysiology revisited.
Sorensen PS. Sorensen PS. Lancet Neurol. 2005 Jan;4(1):9-10. doi: 10.1016/S1474-4422(04)00948-2. Lancet Neurol. 2005. PMID: 15620850 Review. No abstract available.
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Roxburgh RH, et al. Among authors: sorensen ps. Neurology. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8. Neurology. 2005. PMID: 15824338
391 results